Your browser doesn't support javascript.
Confirmed circulation of SARS-CoV-2 in Irish blood donors prior to first national notification of infection.
Butler, Dearbhla; Coyne, Dermot; Pomeroy, Louise; Williams, Pádraig; Holder, Paul; Carterson, Alex; Field, Stephen; Waters, Allison; O'Flaherty, Niamh.
  • Butler D; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland.
  • Coyne D; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland.
  • Pomeroy L; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland.
  • Williams P; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland.
  • Holder P; National Virus Reference Laboratory, University College Dublin, Dublin 4, Ireland.
  • Carterson A; Abbott Laboratories, 100 Abbott park road, Abbott park, IL 60064, United States of America.
  • Field S; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland; School of Medicine, Trinity College Dublin, Ireland.
  • Waters A; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland.
  • O'Flaherty N; Irish Blood Transfusion Service, National Blood Centre, James's Street, Dublin, D08 NH5R, Ireland; National Virus Reference Laboratory, University College Dublin, Dublin 4, Ireland. Electronic address: Niamh.OFlaherty@ibts.ie.
J Clin Virol ; 146: 105045, 2022 01.
Article in English | MEDLINE | ID: covidwho-1531548
ABSTRACT

INTRODUCTION:

Blood donor studies offer a unique opportunity to screen healthy populations for the presence of antibodies to emerging infections. We describe the use of blood donor specimens to track the 'first-wave' of the COVID-19 pandemic in Ireland.

METHODOLOGY:

A random selection of donor samples received by the Irish Blood Transfusion Service (IBTS) between February and September 2020 (n = 8,509) were screened by multiple commercial SARs-CoV-2 antibody assays. The antibody detection rate was adjusted to the population to determine the SARS-CoV-2 seroprevalence in Ireland.

RESULTS:

SARS-CoV-2 antibody detection rose significantly during the first peak of COVID-19 infection, increasing from 0.3% in March, to 2.9% in April (p < 0.0001, The first SARS-CoV-2 antibody positive donor samples were collected on the 17th February 2020, 2 weeks prior to the first official notification. This is the earliest serological evidence of SARS-CoV-2 circulating in the Irish population. Our results also show a significantly higher antibody prevalence in the Capital city and in donors less than 40 years of age.

CONCLUSIONS:

The present study demonstrates evidence of SARS-CoV-2 antibody reactivity across all age groups and counties. The critical value of blood donor seroprevalence studies is apparent in this report which identified the earliest serological evidence of SARS-CoV-2 infection in Ireland, as well as documenting the evolution of COVID-19 pandemic in Ireland over time.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: J.jcv.2021.105045

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Type of study: Experimental Studies / Observational study / Randomized controlled trials Limits: Humans Language: English Journal: J Clin Virol Journal subject: Virology Year: 2022 Document Type: Article Affiliation country: J.jcv.2021.105045